Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
10 pending office actions • 5 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Janssen Pharmaceuticals Inc. manages 10 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 10 actions are spread across 5 distinct art units and 9 distinct examiners. Ilia I Ouspenski is the busiest examiner, currently overseeing 2 pending office actions. The 2 pending actions with the busiest examiner are a portion of the 10 pending office actions. The 9 distinct examiners for 10 pending office actions indicate that almost every matter is handled by a different individual. This requires a strategy that accounts for 9 different examiner styles. The 5 distinct art units reflect a range of subject matter within the biotechnology sector. With 9 distinct examiners and 5 distinct art units, the 10 pending office actions are subject to a variety of examination practices.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (10%) |
| §101 + other | 1 (10%) |
| §103 only | 2 (20%) |
| Double-patenting + other | 3 (30%) |
| Multi-statute (no §101) | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 2 | 77.5% | +20.4% |
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
| WILLIAMS, CATHERINE SERKE | 1 | 63.0% | +29.1% |
| BOUCHELLE, LAURA A | 1 | 80.2% | +10.7% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| WANG, RUIXUE | 1 | 57.4% | +17.8% |
| VU, QUYNH-NHU HOANG | 1 | 68.5% | +27.4% |
| SIMMONS, VALERIE MICHELLE | 1 | 28.9% | +46.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17763600 | MEASURING PARAMETERS ASSOCIATED WITH DRUG ADMINISTRATION AND DRUG ADMINISTRATION DEVICES INCORPORATING SAME | VU, QUYNH-NHU HOANG | 33d |
| 19029331 | MDR E. COLI IMMUNOGEN | GANGLE, BRIAN J | — |
| 18841723 | SMART LIQUID DRUG ADMINISTRATION | WILLIAMS, CATHERINE SERKE | — |
| 17763585 | DRUG DELIVERY ADJUSTMENT | BOUCHELLE, LAURA A | — |
| 18045525 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | OUSPENSKI, ILIA I | — |
| 17240648 | METHOD FOR IDENTIFICATION AND QUANTIFICATION OF POLYSACCHARIDES IN COMPLEX GLYCOCONJUGATE COMPOSITIONS | SIMMONS, VALERIE MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998592 | STABILIZED CORONAVIRUS SPIKE PROTEIN FUSION PROTEINS | WANG, RUIXUE | 170d overdue |
| 17763600 | MEASURING PARAMETERS ASSOCIATED WITH DRUG ADMINISTRATION AND DRUG ADMINISTRATION DEVICES INCORPORATING SAME | VU, QUYNH-NHU HOANG | 33d |
| 19029331 | MDR E. COLI IMMUNOGEN | GANGLE, BRIAN J | — |
| 19023669 | COMPOSITIONS COMPRISING ATICAPRANT | YOUNG, MICAH PAUL | — |
| 18841723 | SMART LIQUID DRUG ADMINISTRATION | WILLIAMS, CATHERINE SERKE | — |
| 17763585 | DRUG DELIVERY ADJUSTMENT | BOUCHELLE, LAURA A | — |
| 18498448 | COMPOSITIONS AND METHODS FOR ENHANCING GENE EXPRESSION | GROOMS, TIFFANY NICOLE | — |
| 18317498 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 3783 | 2 |
| 1644 | 2 |
| 1637 | 1 |
| 1672 | 1 |
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19029331 | MDR E. COLI IMMUNOGEN | GANGLE, BRIAN J | — | §101§112DP | Non-Final OA | — | Pending | Jan 17, 2025 |
| 19023669 | COMPOSITIONS COMPRISING ATICAPRANT | YOUNG, MICAH PAUL | — | §103DP | Non-Final OA | — | Pending | Jan 16, 2025 |
| 18841723 | SMART LIQUID DRUG ADMINISTRATION | WILLIAMS, CATHERINE SERKE | — | §102§103 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 17763585 | DRUG DELIVERY ADJUSTMENT | BOUCHELLE, LAURA A | 3783 | §102§103 | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18498448 | COMPOSITIONS AND METHODS FOR ENHANCING GENE EXPRESSION | GROOMS, TIFFANY NICOLE | 1637 | §103DP | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18317498 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | May 15, 2023 |
| 17998592 | STABILIZED CORONAVIRUS SPIKE PROTEIN FUSION PROTEINS | WANG, RUIXUE | 1672 | §103 | Non-Final OA | 170d overdue | Pending | Nov 11, 2022 |
| 18045525 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | OUSPENSKI, ILIA I | 1644 | §101Other | Non-Final OA | — | Pending | Oct 11, 2022 |
| 17763600 | MEASURING PARAMETERS ASSOCIATED WITH DRUG ADMINISTRATION AND DRUG ADMINISTRATION DEVICES INCORPORATING SAME | VU, QUYNH-NHU HOANG | 3783 | §102§103 | Non-Final OA | 33d | Pending | Mar 24, 2022 |
| 17240648 | METHOD FOR IDENTIFICATION AND QUANTIFICATION OF POLYSACCHARIDES IN COMPLEX GLYCOCONJUGATE COMPOSITIONS | SIMMONS, VALERIE MICHELLE | 1758 | §103 | Final Rejection | — | Pending | Apr 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial